Cancer Gene Therapy Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The global cancer gene therapy market was valued at USD 5.52 Billion in 2025. It is poised to grow at a CAGR of 18.90% during the forecast period of 2026-2035, and reach USD 31.17 Billion by 2035. The market is driven by the rising global cancer burden and the growing demand for precise, gene-targeted treatment strategies.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Cancer Gene Therapy Market

United States: The Cancer Gene Therapy Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. Petrochemical-derived pharmaceutical packaging materials including blister packs, polymer bottles, and specialty film coatings are facing 15-20% cost inflation from the Gulf supply disruption. API production costs are rising as petrochemical reagent prices increase 15-20%. Air freight costs have spiked dramatically, with temperature-sensitive pharmaceutical distribution facing elevated costs and extended lead times as Gulf carrier networks remain suspended. Consumer spending caution is growing as gasoline above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets. Clinical trial operations in Middle Eastern investigator sites have been disrupted, and medical supply chains face elevated logistics costs.

Iran: Iran's healthcare system has been severely damaged by the conflict, with the WHO identifying at least 13 health facilities as conflict-damaged. The domestic pharmaceutical and medical device sector, already severely constrained by sanctions limiting access to Western medical technology and APIs, has been further disrupted by power outages, workforce displacement, and the collapse of medical supply chain logistics. Iranian patients requiring treatment for cancer gene therapy conditions face an acute access crisis, as hospital operations are redirected toward treating conflict casualties and basic medical supplies are running low.

Israel: Israel's pharmaceutical and medical device sector is operating under emergency conditions. Israeli hospitals have moved some operations underground, medical resources are being prioritised for conflict casualties, and elective and non-emergency healthcare consumption has declined. However, Israel's biopharmaceutical research base continues to operate, with several Israeli companies involved in novel treatment development for cancer gene therapy indications. Post-conflict, Israel's healthcare system is expected to invest significantly in medical technology and pharmaceutical infrastructure restoration and capacity expansion.

Key Takeaways

Government

• Relevant health authorities should activate emergency pharmaceutical supply chain resilience protocols, ensuring that API and packaging material sourcing for essential cancer gene therapy treatments is not concentrated in Gulf-adjacent supply chains exposed to maritime disruption.
• Regulatory agencies should fast-track review of treatment availability and consider emergency compassionate use extensions for patients in conflict-affected regions who face interruption to their standard of care.
• Governments should monitor petrochemical-derived pharmaceutical packaging cost inflation, ensuring that price increases remain within access thresholds for patients requiring ongoing cancer gene therapy treatment.

Market

• Petrochemical-derived pharmaceutical packaging and API precursor costs are rising 15-20%, creating margin compression for cancer gene therapy manufacturers in the near term, with limited ability to pass costs through in price-regulated markets.
• The conflict's disruption to clinical trial infrastructure in Middle Eastern sites may modestly delay regulatory submissions and new treatment launches that had enrolled patients from the region, though the structural market growth trajectory remains intact.
• Healthcare system demand for cancer gene therapy treatment is fundamentally driven by disease burden and demographics rather than geopolitical events, providing strong structural insulation for the market's long-term growth trajectory.

Procurement

• Pharmaceutical procurement teams should build 90-day safety stock for essential cancer gene therapy treatment drugs and biological agents, hedging against further pharmaceutical logistics cost increases and potential supply disruptions.
• API and excipient buyers should review single-source supplier risks for Gulf-adjacent petrochemical-derived pharmaceutical inputs, establishing secondary supply arrangements with non-Gulf origin manufacturers in India, China, and Europe.
• Hospital pharmacy procurement managers should review cold-chain logistics contracts for temperature-sensitive cancer gene therapy therapeutics, ensuring that alternative air routing through non-conflict-zone hubs is available if Gulf carrier services remain suspended.

Key Market Trends and Insights

• By therapy type, gene-induced immunotherapy held approximately 38% in the historical period.
• Based on the indication, the lung cancer segment is likely to lead the market in the forecast period.
• Based on the region, North America held approximately 65% market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 5.52 Billion
• Projected Market Size (2035): USD 31.17 Billion
• CAGR (2026-2035): 18.90%

Cancer Gene Therapy Market Overview

Cancer gene therapy is advancing rapidly as innovative techniques enable precise genetic modification to target malignancies more effectively. Approaches such as viral vector delivery, AAV gene therapy, and lentiviral vector systems support therapies including CRISPR cancer therapy, gene silencing, and gene correction, while oncolytic virus strategies and tumor suppressor gene restoration enhance therapeutic outcomes through in vivo gene editing and ex vivo gene therapy. The market is poised to grow at a CAGR of 18.90% during the forecast period of 2026-2035, supported by regulatory progress, investment expansion, and continuous innovation in targeted oncology treatments. The growth is further driven by rising cancer prevalence, expanding clinical pipelines, and increasing adoption of advanced genetic technologies.

Cancer Gene Therapy Market Growth Drivers

Rising Global Cancer Burden to Strengthen the Market Demand

The escalating global cancer burden is a primary driver of demand for innovative gene-based therapeutic solutions. According to Freddie Bray, et al., 2024, an estimated 20 million new cancer cases were diagnosed globally in 2022, with approximately 9.7 million associated deaths recorded in the same year. The agency further projects that annual global cancer cases could reach approximately 35 million by 2050, driven by population growth and demographic aging. This rising incidence is accelerating the adoption of gene therapy approaches that offer tumor-specific targeting and the potential for durable remission with reduced systemic toxicity compared to conventional chemotherapy and radiation-based treatments.

Cancer Gene Therapy Market Trends

Increasing Strategic Acquisitions to Boost the Market Value

Strategic acquisitions are reshaping the cancer gene therapy landscape by enabling pharmaceutical companies to rapidly augment precision oncology portfolios. For instance, in January 2024, Kyowa Kirin Co., Ltd. acquired Orchard Therapeutics plc, enhancing its hematopoietic stem cell gene therapy capabilities and pipeline. This integration supports advancements in molecular profiling, patient stratification, and biomarker-based treatment, with broader applications in oncology, including AI diagnostics and personalized dosing, thereby driving sustained market expansion.

Cancer Gene Therapy Market Segmentation

Market Breakup by Therapy Type

• Gene Transfer
• Gene Induced Immunotherapy
• Oncolytic Virotherapy
• Others

Market Breakup by Indication

• Breast Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Lung Cancer
• Liver Cancer
• Prostate Cancer
• Others

Market Breakup by End User

• Hospitals
• Cancer Centers
• Research and Academic Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Cancer Gene Therapy Market Share

Gene Induced Immunotherapy Segment is Poised to Dominate the Market Segmentation by Therapy Type

The market is segmented by therapy type into gene transfer, gene-induced immunotherapy, oncolytic virotherapy, and others. Among these, gene-induced immunotherapy is expected to lead the market, driven by the widespread clinical adoption of CAR-T cell therapies for hematological malignancies and an expanding regulatory evidence base. In August 2024, the FDA approved afami-cel (Tecelra), the first T-cell receptor (TCR)-based cell therapy for cancer, for metastatic synovial sarcoma, with tumors shrinking in approximately 43% of patients in the pivotal trial. This broadening regulatory landscape continues to reinforce the dominant position of immunotherapy-based modalities within the cancer gene therapy market.

Cancer Gene Therapy Market Analysis by Region

North America is expected to dominate the market due to its advanced healthcare infrastructure, strong presence of leading biotechnology firms, and high adoption of innovative therapies. The region benefits from significant research funding and a well-established clinical trial ecosystem, supporting rapid development and commercialization. Additionally, favorable regulatory support from the U.S. Food and Drug Administration and rising cancer prevalence further drive market growth. Increasing investments in precision medicine and strong industry-academia collaborations continue to reinforce the region’s leadership throughout the forecast period.

Leading Players in the Cancer Gene Therapy Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a gene therapy company specializing in autologous cell and gene therapies for severe genetic diseases. The company received FDA approval for Zevaskyn (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa, making it the first autologous cell sheet-based gene therapy approved for this indication. Zevaskyn holds Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, reflecting the strength of its clinical and regulatory profile.

Asklepios BioPharmaceutical Inc.

Asklepios BioPharmaceutical Inc. (AskBio) is a gene therapy company utilizing adeno-associated virus (AAV) vector technology across cardiovascular, central nervous system, and neuromuscular conditions. In October 2025, the company's investigational AAV-based program AB-1003 (LION-101) for limb-girdle muscular dystrophy demonstrated a favorable safety profile with no serious adverse events or dose-limiting toxicities reported at up to 52 weeks post-treatment, reflecting advancing safety standards within the gene therapy delivery field.

NantKwest, Inc.

NantKwest, Inc., now operating as ImmunityBio, is a biopharmaceutical company developing cellular immunotherapy and immunogene therapies using natural killer (NK) cell and T-cell platforms to treat cancer. In April 2024, Anktiva (N-803) received FDA approval for BCG-unresponsive non-muscle-invasive bladder cancer, marking a significant regulatory milestone and reinforcing the commercial viability of its immunogene therapy approach in oncological indications.

Bluebird bio Inc.

Bluebird bio Inc. is a gene therapy company focused on severe genetic diseases using lentiviral vector technology. Its portfolio includes Zynteglo for transfusion-dependent beta-thalassemia and Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy. The company is actively advancing its pipeline, supporting patient stratification and personalized dosing in gene therapy applications.

Other key players in the market are Bristol-Myers Squibb, Elevate Bio Inc., Glaxo Smith Kline Inc., and Genelux Corporation.

Key Questions Answered in the Cancer Gene Therapy Market Report

• What was the cancer gene therapy market value in 2025?
• What is the cancer gene therapy market forecast outlook for 2026-2035?
• What major factors aid the demand for the cancer gene therapy market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major cancer gene therapy market trends?
• Which therapy type is expected to dominate the market segment?
• Which indication is projected to lead the market segment?
• Which end user is anticipated to drive the market segment?
• Who are the key players in the cancer gene therapy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?